Interferon News and Research

RSS

Three Rivers Pharmaceuticals receives FDA expanded labeling for INFERGEN

Three Rivers Pharmaceuticals, LLC, today received expanded labeling from the U.S. Food and Drug Administration (FDA) to include daily use of INFERGEN (Consensus Interferon) in combination with ribavirin (RBV) for retreatment of chronic hepatitis C patients. The expanded labeling targets hepatitis C patients who need retreatment.

6 Jul 2010

CDC issues new guidelines on detection of Mycobacterium tuberculosis infections

Today the United States Centers for Disease Control and Prevention issued new and important guidelines on the detection of Mycobacterium tuberculosis infections, the causative agent of tuberculosis. In these landmark guidelines, CDC advises that Interferon Gamma Release Assay blood tests are now preferred over the 100+-year-old tuberculin skin test for diagnosing TB infection in certain populations, including people who typically do not return for the necessary reading of TST results, and those who have received Bacille Calmette-Guerin as a vaccine or for cancer therapy

1 Jul 2010

Bortezomib may offer hope for treating inflammatory diseases: New research

Those looking for a new treatment for a range of inflammatory diseases like arthritis, multiple sclerosis, inflammatory bowel disease, and lupus may need to look no further than a drug already available for treating cancer. In a research report published in the July 2010 print issue of the Journal of Leukocyte Biology, Japanese scientists use mice to show that bortezomib, currently used to treat cancers that affect white blood cells, induces cell death only in harmful (active and proliferating) T cells, leaving the rest unharmed.

1 Jul 2010

Research provides hope and encouragement to people living with lupus

Research presented during the 9th International Lupus Congress held in Vancouver, Canada from June 24-27, 2010 should give hope and encouragement for the future of the treatment and management of lupus to the 1.5 million Americans and 5 million people worldwide living with lupus. In recent years, there have been significant advances made in many areas of lupus research including the development of new treatments, adult stem cell transplantation, genetics, lupus-related cardiovascular disease, and quality of life issues for people with lupus.

25 Jun 2010

Positive results from Phase II PK study for Topical Interferon Alpha-2b announced

Helix BioPharma Corp. today announced positive Phase II pharmacokinetic findings for Topical Interferon Alpha-2b in patients with low-grade cervical lesions.

24 Jun 2010

VCU researchers discover mechanism that regulates gene expression and growth in melanoma cells

Virginia Commonwealth University researchers have discovered a mechanism by which an enzyme regulates gene expression and growth in melanoma cells, a finding that could someday lead to more effective drugs to attack cancers and make them more treatable.

18 Jun 2010

Hemispherx announces exclusive revenue sharing agreement with GP Pharm

Hemispherx Biopharma, Inc., announced that the Company executed an exclusive revenue sharing Sales, Marketing, Distribution and Supply Agreement for Argentina with GP Pharm Latinoamerica, an affiliate company of Spanish GP Pharm SA.

16 Jun 2010

Biogen Idec initiates enrollment in Phase II BG-12 combination trial for relapsing-remitting multiple sclerosis

Biogen Idec today announced enrollment of the first patient in a multicenter Phase II clinical trial designed to evaluate its investigational oral therapy BG-12 (dimethyl fumarate) in combination with commonly used first-line treatments in patients with relapsing-remitting multiple sclerosis (RRMS).

15 Jun 2010

FDA grants Fast Track status for Genzyme's alemtuzumab development program for MS

Genzyme Corporation announced today that its alemtuzumab for multiple sclerosis development program has been granted Fast Track status by the U.S. Food and Drug Administration (FDA). This designation covers patients with relapsing-remitting forms of the disease.

15 Jun 2010

Genetic variation can predict how people infected with hepatitis C react to treatment: Scientists

A small genetic change can predict how people infected with hepatitis C react to treatment, paving the way to personalised therapy for this difficult to treat disease, the annual conference of the European Society of Human Genetics will hear today (Sunday 13 June). Dr. Zoltan Kutalik, from the Department of Medical Genetics, University of Lausanne, Switzerland, will tell delegates that individuals with this change, in a gene encoding for the antiviral cytokine (cell-signalling molecule) interferon lamda, reacts less well to treatment.

14 Jun 2010

$Data from Phase 1 study of FOLOTYN in patients with relapsed or refractory CTCL presented at EHA 2010$

Data from Phase 1 study of FOLOTYN in patients with relapsed or refractory CTCL presented at EHA 2010

Allos Therapeutics, Inc. today announced updated data from its ongoing dose finding Phase 1 study of FOLOTYN (pralatrexate injection) in patients with relapsed or refractory cutaneous T-cell lymphoma, a group of often slow-growing non-Hodgkins lymphomas that primarily manifest in the skin. These data were presented during a poster presentation at the European Hematology Association meeting being held June 10-13, 2010 in Barcelona, Spain.

11 Jun 2010

Helix BioPharma third-quarter revenues increase 20.6%

Helix BioPharma Corp. today announced financial results for the third quarter ended April 30, 2010.

11 Jun 2010

FDA advisory committee recommends approval of Novartis' FTY720 for relapsing MS

Today, an advisory committee of the US Food and Drug Administration (FDA) recommended approval of FTY720 (fingolimod) for the treatment of patients with relapsing multiple sclerosis, the most common form of the disease. The FDA has the option of seeking the advice of one of its advisory committees as it reviews and decides whether to approve a new treatment. The committee voted unanimously that FTY720 demonstrated substantial efficacy in treating relapsing remitting MS and that safety of the proposed 0.5 mg dose justified approval.

11 Jun 2010

Gamma interferon wakes-up sleeping stem cells to produce immune system cells to fight invading bacteria

Most of the time, the body's blood-forming (hematopoietic) stem cells remain dormant, with just a few producing blood cells and maintaining a balance among the different types.

10 Jun 2010

Interim results from PROPEL study of RG7128 submitted as abstract to AASLD for Annual Liver Meeting

Pharmasset, Inc. announced today that the interim results from the PROPEL study conducted by its partner Roche demonstrate that RG7128 triple combination therapy was safe and well tolerated. In that study, the safety profile of RG7128 (1000mg BID or 500mg BID), when administered for 8 or 12 weeks with Pegasys (peginterferon alfa-2a) and Copegus (ribavirin), the standard of care, was similar to the safety profile of SOC alone.

9 Jun 2010

Helix BioPharma reports Phase II clinical results of Topical Interferon Alpha-2b for ano-genital warts

Helix BioPharma Corp. today announced results from the Phase II clinical trial assessing the efficacy and safety of Topical Interferon Alpha-2b cream for the treatment of ano-genital warts (AGW).

9 Jun 2010

Idera reports preliminary results from IMO-3100 Phase 1 clinical trial for autoimmune, inflammatory diseases

Idera Pharmaceuticals, Inc. today announced preliminary results from a Phase 1 clinical trial of IMO-3100, its lead Toll-like Receptor (TLR) 7 and TLR9 antagonist drug candidate for potential applications in autoimmune and inflammatory diseases. In this trial, healthy subjects in five dosage cohorts received single doses of IMO-3100 from 0.04 to 0.64 mg/kg. IMO-3100 was well tolerated at all dose levels.

8 Jun 2010

Researchers decipher how mast cells set immune defense on right track

In the event of an infection, the immune system releases messenger substances. These molecules can either activate immune cells to defeat invading pathogens, or inhibit them to prevent an excessive immune reaction. For this, the immune system has to decide very quickly what mixture of activating and inhibiting messenger molecules leads to a successful defence.

8 Jun 2010

Sanofi-aventis reports new 1-year data from teriflunomide Phase II study for relapsing multiple sclerosis

Sanofi-aventis reported today new one-year data from a Phase II study with teriflunomide, a novel oral disease modifier being investigated for the treatment of relapsing multiple sclerosis (RMS). Study results demonstrated an improvement in outcomes, with a consistent safety profile with the data from a previous Phase II monotherapy study, in patients treated with interferon beta (IFN-[BETA]) - a standard therapy in RMS - and receiving teriflunomide 7mg or 14mg, compared with patients treated with IFN-[BETA] and receiving oral placebo.

7 Jun 2010

Preclinical data of dual TLR7 and TLR8 agonist in cancer published

Idera Pharmaceuticals, Inc. today announced the publication of data from studies of a dual agonist of Toll-like Receptor 7 and TLR8 in preclinical models of cancer. The Company created this first-in-class RNA-based dual agonist of TLR7 and TLR8 through its chemistry-based approach to identifying novel TLR-targeted drug candidates.

4 Jun 2010

Interferon News and Research

Three Rivers Pharmaceuticals receives FDA expanded labeling for INFERGEN

CDC issues new guidelines on detection of Mycobacterium tuberculosis infections

Bortezomib may offer hope for treating inflammatory diseases: New research

Research provides hope and encouragement to people living with lupus

Positive results from Phase II PK study for Topical Interferon Alpha-2b announced

VCU researchers discover mechanism that regulates gene expression and growth in melanoma cells

Hemispherx announces exclusive revenue sharing agreement with GP Pharm

Biogen Idec initiates enrollment in Phase II BG-12 combination trial for relapsing-remitting multiple sclerosis

FDA grants Fast Track status for Genzyme's alemtuzumab development program for MS

Genetic variation can predict how people infected with hepatitis C react to treatment: Scientists

Data from Phase 1 study of FOLOTYN in patients with relapsed or refractory CTCL presented at EHA 2010

Helix BioPharma third-quarter revenues increase 20.6%

FDA advisory committee recommends approval of Novartis' FTY720 for relapsing MS

Gamma interferon wakes-up sleeping stem cells to produce immune system cells to fight invading bacteria

Interim results from PROPEL study of RG7128 submitted as abstract to AASLD for Annual Liver Meeting

Helix BioPharma reports Phase II clinical results of Topical Interferon Alpha-2b for ano-genital warts

Idera reports preliminary results from IMO-3100 Phase 1 clinical trial for autoimmune, inflammatory diseases

Researchers decipher how mast cells set immune defense on right track

Sanofi-aventis reports new 1-year data from teriflunomide Phase II study for relapsing multiple sclerosis

Preclinical data of dual TLR7 and TLR8 agonist in cancer published

Advancing Intracellular Delivery with LumiPore®

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

The role of UV-Vis in biopharma QC

Latest News